erlotinib
UkraineDrugs containing this active substance
-
The drug is prescribed for the treatment of non-small cell lung cancer (as first-line therapy, for maintenance therapy, or after ineffective chemotherapy) and for the treatment of metastatic pancreatic cancer in combination with gemcitabine.
Form: tablets, film-coated
Active substance Dosage erlotinib 25 mg ATC: L01EB02
Manufacturer: Hetero Labs Limited
-
The drug is used for the treatment of non-small cell lung cancer (as first-line therapy in the presence of certain mutations, for maintenance therapy, or after ineffective chemotherapy) and for the treatment of metastatic pancreatic cancer in combination with gemcitabine.
Form: tablets, film-coated
Active substance Dosage erlotinib 100 mg ATC: L01EB02
Manufacturer: Hetero Labs Limited
-
The drug is used for the treatment of non-small cell lung cancer (as first-line therapy, for maintenance treatment, or after ineffective chemotherapy) and for the treatment of metastatic pancreatic cancer in combination with gemcitabine.
Form: tablets, film-coated
Active substance Dosage erlotinib 150 mg ATC: L01EB02
Manufacturer: Hetero Labs Limited
-
The drug is used for the treatment of non-small cell lung cancer (as first-line therapy in the presence of certain mutations, for maintenance therapy, or after ineffective chemotherapy) and for the treatment of metastatic pancreatic cancer in combination with gemcitabine.
Form: tablets, film-coated
Active substance Dosage erlotinib 25 mg ATC: L01EB02
Manufacturer: KRKA, d.d., Novo mesto (batch control and batch release) / KRKA, d.d., Novo mesto (secondary packaging)
-
The drug is used for the treatment of non-small cell lung cancer (as first-line therapy in the presence of certain mutations, for maintenance therapy, or after ineffective chemotherapy) and for the treatment of metastatic pancreatic cancer in combination with gemcitabine.
Form: tablets, film-coated
Active substance Dosage erlotinib 100 mg ATC: L01EB02
Manufacturer: KRKA, d.d., Novo mesto (batch control and batch release) / KRKA, d.d., Novo mesto (secondary packaging)
-
The drug is used for the treatment of non-small cell lung cancer (as first-line therapy, for maintenance therapy, or after ineffective chemotherapy) and for the treatment of metastatic pancreatic cancer in combination with gemcitabine.
Form: tablets, film-coated
Active substance Dosage erlotinib 150 mg ATC: L01EB02
Manufacturer: KRKA, d.d., Novo Mesto (batch control and batch release)/KRKA, d.d., Novo Mesto (secondary packaging)
-
The drug is used for the treatment of non-small cell lung cancer (as first-line therapy or for maintenance after chemotherapy) and metastatic pancreatic cancer (in combination with gemcitabine).
Form: tablets, film-coated
Active substance Dosage erlotinib 100 mg ATC: L01EB02
Manufacturer: Shilpa Medicare Limited (full production cycle; quality control and stability testing (physical and chemical tests))
-
The drug is used for the treatment of non-small cell lung cancer (in the presence of certain EGFR mutations) and metastatic pancreatic cancer (in combination with gemcitabine).
Form: tablets, film-coated
Active substance Dosage erlotinib 150 mg ATC: L01EB02
Manufacturer: Shilpa Medicare Limited (full production cycle; quality control and stability testing (physical and chemical tests))
-
The drug is used for the treatment of non-small cell lung cancer (in the presence of certain EGFR mutations) and metastatic pancreatic cancer (in combination with gemcitabine).
Form: tablets, film-coated
Active substance Dosage erlotinib 25 mg ATC: L01EB02
Manufacturer: Shilpa Medicare Limited (full production cycle; quality control and stability testing (physical and chemical tests))
-
The drug is prescribed for the treatment of non-small cell lung cancer (as first-line therapy in the presence of certain mutations, for maintenance therapy, or after ineffective chemotherapy), as well as for the treatment of metastatic pancreatic cancer in combination with gemcitabine.
Form: tablets, film-coated
Active substance Dosage erlotinib 25 mg ATC: L01EB02
Manufacturer: Remedica Limited
-
The drug is prescribed for the treatment of non-small cell lung cancer (as first-line therapy in the presence of certain mutations, as maintenance therapy, or after ineffective chemotherapy), as well as for the treatment of metastatic pancreatic cancer in combination with gemcitabine.
Form: tablets, film-coated
Active substance Dosage erlotinib 50 mg ATC: L01EB02
Manufacturer: Remedica Limited
-
The drug is used for the treatment of non-small cell lung cancer (as first-line therapy or for maintenance after chemotherapy) and for the treatment of metastatic pancreatic cancer in combination with gemcitabine.
Form: tablets, film-coated
Active substance Dosage erlotinib 100 mg ATC: L01EB02
Manufacturer: Remedica Limited
-
The drug is prescribed for the treatment of non-small cell lung cancer (as first-line therapy, as maintenance therapy, or after ineffective chemotherapy) and for the treatment of metastatic pancreatic cancer in combination with gemcitabine.
Form: tablets, film-coated
Active substance Dosage erlotinib 150 mg ATC: L01EB02
Manufacturer: Remedica Limited
-
The drug is used for the treatment of non-small cell lung cancer (as first-line therapy in the presence of certain mutations, or as maintenance therapy) and for the treatment of metastatic pancreatic cancer in combination with gemcitabine.
Form: tablets, film-coated
Active substance Dosage erlotinib 25 mg ATC: L01XE03
Manufacturer: Reliance Life Sciences Private Limited (Plant 6)
-
The drug is prescribed for the treatment of non-small cell lung cancer (as first-line therapy in the presence of certain mutations, as maintenance therapy, or after ineffective chemotherapy), as well as for the treatment of metastatic pancreatic cancer in combination with gemcitabine.
Form: tablets, film-coated
Active substance Dosage erlotinib 100 mg ATC: L01XE03
Manufacturer: Reliance Life Sciences Private Limited (Plant 6)
-
The drug is used for the treatment of non-small cell lung cancer (as first-line therapy in the presence of certain mutations, or as maintenance therapy) and for the treatment of metastatic pancreatic cancer in combination with gemcitabine.
Form: tablets, film-coated
Active substance Dosage erlotinib 150 mg ATC: L01XE03
Manufacturer: Reliance Life Sciences Private Limited (Plant 6)
-
The drug is used for the treatment of non-small cell lung cancer (as first-line therapy or for maintenance after chemotherapy) and metastatic pancreatic cancer (in combination with gemcitabine).
Form: tablets, film-coated
Active substance Dosage erlotinib 100 mg ATC: L01XE03
Manufacturer: NOBEL ILAC SANAYI VE TICARET A.S.
-
The drug is used for the treatment of non-small cell lung cancer (as first-line therapy in the presence of certain mutations, for maintenance therapy, or after ineffective chemotherapy), as well as for the treatment of metastatic pancreatic cancer in combination with gemcitabine.
Form: tablets, film-coated
Active substance Dosage erlotinib 150 mg ATC: L01XE03
Manufacturer: NOBEL ILAC SANAYI VE TICARET A.S.
-
The drug is prescribed for the treatment of non-small cell lung cancer (as first-line therapy in the presence of certain mutations, for maintenance therapy, or after ineffective chemotherapy), as well as for the treatment of metastatic pancreatic cancer in combination with gemcitabine.
Form: tablets, film-coated
Active substance Dosage erlotinib 100 mg ATC: L01EB02
Manufacturer: Farmadoks Healthcare Ltd. (quality control/testing)
-
The drug is used for the treatment of non-small cell lung cancer (as first-line therapy, for maintenance therapy, or after ineffective chemotherapy) and metastatic pancreatic cancer (in combination with gemcitabine).
Form: tablets, film-coated
Active substance Dosage erlotinib 150 mg ATC: L01EB02
Manufacturer: Farmadoks Healthcare Ltd. (quality control/testing)